Department of Kinesiology, The Pennsylvania State University, 113 Noll Lab, Univ. Park, PA 16802, USA.
J Appl Physiol (1985). 2010 Jun;108(6):1575-81. doi: 10.1152/japplphysiol.01362.2009. Epub 2010 Apr 1.
Chronic systemic platelet cyclooxygenase (COX) inhibition with low-dose aspirin [acetylsalicylic acid (ASA)] significantly attenuates reflex cutaneous vasodilation in middle-aged humans, whereas acute, localized, nonisoform-specific inhibition of vascular COX with intradermal administration of ketorolac does not alter skin blood flow during hyperthermia. Taken together, these data suggest that platelets may be involved in reflex cutaneous vasodilation, and this response is inhibited with systemic pharmacological platelet inhibition. We hypothesized that, similar to ASA, specific platelet ADP receptor inhibition with clopidogrel would attenuate reflex vasodilation in middle-aged skin. In a double-blind crossover design, 10 subjects (53+/-2 yr) were instrumented with four microdialysis fibers for localized drug administration and heated to increase body core temperature [oral temperature (Tor)] 1 degrees C during no systemic drug (ND), and after 7 days of systemic ASA (81 mg) and clopidogrel (75 mg) treatment. Skin blood flow (SkBF) was measured using laser-Doppler flowmetry over each site assigned as 1) control, 2) nitric oxide synthase inhibited (NOS-I; 10 mM NG-nitro-L-arginine methyl ester), 3) COX inhibited (COX-I; 10 mM ketorolac), and 4) NOS-I+COX-I. Data were normalized and presented as a percentage of maximal cutaneous vascular conductance (%CVCmax; 28 mM sodium nitroprusside+local heating to 43 degrees C). During ND conditions, SkBF with change (Delta) in Tor=1.0 degrees C was 56+/-3% CVCmax. Systemic low-dose ASA and clopidogrel both attenuated reflex vasodilation (ASA: 43+/-3; clopidogrel: 32+/-3% CVCmax; both P<0.001). In all trials, localized COX-I did not alter SkBF during significant hyperthermia (ND: 56+/-7; ASA: 43+/-5; clopidogrel: 35+/-5% CVCmax; all P>0.05). NOS-I attenuated vasodilation in ND and ASA (ND: 28+/-6; ASA: 25+/-4% CVCmax; both P<0.001), but not with clopidogrel (27+/-4% CVCmax; P>0.05). NOS-I+COX-I was not different compared with NOS-I alone in either systemic treatment condition. Both systemic ASA and clopidogrel reduced the time required to increase Tor 1 degrees C (ND: 58+/-3 vs. ASA: 45+/-2; clopidogrel: 39+/-2 min; both P<0.001). ASA-induced COX and specific platelet ADP receptor inhibition attenuate reflex vasodilation, suggesting platelet involvement in reflex vasodilation through the release of vasodilating factors.
慢性全身性血小板环氧化酶(COX)抑制作用(低剂量阿司匹林[乙酰水杨酸(ASA)])可显著减弱中年人类的反射性皮肤血管扩张,而局部、非同型特异性抑制血管 COX(使用酮咯酸进行皮内给药)则不会改变发热期间的皮肤血流。综合这些数据表明,血小板可能参与反射性皮肤血管扩张,而这种反应会被全身性药理学血小板抑制所抑制。我们假设,类似于 ASA,使用氯吡格雷特异性抑制血小板 ADP 受体也会减弱中年皮肤的反射性血管扩张。在一项双盲交叉设计中,10 名受试者(53±2 岁)被安置了四个微透析纤维,用于局部药物给药,并在没有全身药物(ND)的情况下,通过升高口腔温度(Tor)1°C来加热,以增加体核温度;之后分别进行了 7 天的全身 ASA(81mg)和氯吡格雷(75mg)治疗。使用激光多普勒流量测定法测量皮肤血流(SkBF),并将每个部位分为以下四个组:1)对照,2)一氧化氮合酶抑制(NOS-I;10mM NG-硝基-L-精氨酸甲酯),3)COX 抑制(COX-I;10mM 酮咯酸),和 4)NOS-I+COX-I。数据经过归一化,并以最大皮肤血管传导率(%CVCmax;28mM 硝普钠+局部加热至 43°C)的百分比表示。在 ND 条件下,Tor 变化(Delta)为 1.0°C 时,SkBF 为 56±3%CVCmax。全身低剂量 ASA 和氯吡格雷均减弱了反射性血管扩张(ASA:43±3%;氯吡格雷:32±3%;均 P<0.001)。在所有试验中,局部 COX-I 在显著发热期间并没有改变 SkBF(ND:56±7;ASA:43±5;氯吡格雷:35±5%;均 P>0.05)。NOS-I 在 ND 和 ASA 中减弱了血管扩张(ND:28±6;ASA:25±4%;均 P<0.001),但在氯吡格雷中没有(27±4%;P>0.05)。NOS-I+COX-I 在两种全身治疗条件下与单独使用 NOS-I 相比没有差异。ASA 和氯吡格雷均减少了升高 Tor 1°C 所需的时间(ND:58±3 与 ASA:45±2;氯吡格雷:39±2min;均 P<0.001)。ASA 诱导的 COX 和特定的血小板 ADP 受体抑制减弱了反射性血管扩张,这表明血小板通过释放血管扩张因子参与反射性血管扩张。